A Phase III Study of Flt3 Ligand (Flt3L) (NSC #696599) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission

Must have morphologic proof of AML (M0-M7 or RAEB-T) and be in >/= 2nd CR, >/= 18 years of age, ECOG performance status of 0 2; patients must be registered and started on treatment within 4 weeks of documentation of CR following induction therapy or within 4 weeks of discharge from hospital following post-remission therapy; no prior immunotherapy or allogeneic transplant; no uncontrolled or active autoimmune disease, no active cardiac or pulmonary disease.